WallStSmart

Gyre Therapeutics Inc. (GYRE)vsRevolution Medicines Inc (RVMD)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Gyre Therapeutics Inc. generates 14700% more annual revenue ($109.82M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -19.3%. RVMD earns a higher WallStSmart Score of 24/100 (F).

GYRE

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 2/9Altman Z: 4.60

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GYRE3 strengths · Avg: 10.0/10
EPS GrowthGrowth
166.2%10/10

Earnings expanding 166.2% YoY

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.6010/10

Safe zone — low bankruptcy risk

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

GYRE4 concerns · Avg: 2.5/10
Market CapQuality
$779.35M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-13.3%2/10

ROE of -13.3% — below average capital efficiency

Revenue GrowthGrowth
-2.1%2/10

Revenue declined 2.1%

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.6x4/10

Trading at 16.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : GYRE

The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : GYRE

The primary concerns for GYRE are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

GYRE profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

GYRE carries more volatility with a beta of 4.83 — expect wider price swings.

GYRE is growing revenue faster at -2.1% — sustainability is the question.

GYRE generates stronger free cash flow (-18M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 23/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Gyre Therapeutics Inc.

HEALTHCARE · BIOTECHNOLOGY · USA

Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?